Cargando…

Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice

INTRODUCTION: Alzheimer's disease (AD) is the most common form of dementia. Beta‐secretase (BACE) inhibitors have been proposed as potential therapeutic interventions; however, initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease. Whethe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oblak, Adrian L., Cope, Zackary A., Quinney, Sara K., Pandey, Ravi S., Biesdorf, Carla, Masters, Andi R., Onos, Kristen D., Haynes, Leslie, Keezer, Kelly J., Meyer, Jill A., Peters, Jonathan S., Persohn, Scott A., Bedwell, Amanda A., Eldridge, Kierra, Speedy, Rachael, Little, Gabriela, Williams, Sean‐Paul, Noarbe, Brenda, Obenaus, Andre, Sasner, Michael, Howell, Gareth R., Carter, Gregory W., Williams, Harriet, Lamb, Bruce T., Territo, Paul R., Sukoff Rizzo, Stacey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281365/ https://www.ncbi.nlm.nih.gov/pubmed/35846156 http://dx.doi.org/10.1002/trc2.12317

Ejemplares similares

Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core study
por: Onos, Kristen D., et al.
Publicado: (2022)

Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease
por: Jullienne, Amandine, et al.
Publicado: (2023)

Plcg2(M28L) Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice
por: Oblak, Adrian L., et al.
Publicado: (2022)

Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
por: Oblak, Adrian L., et al.
Publicado: (2021)

Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
por: Kotredes, Kevin P., et al.
Publicado: (2021)

Corrigendum: Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2(*)R47H
por: Kotredes, Kevin P., et al.
Publicado: (2022)

Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease
por: Cope, Zackary A., et al.
Publicado: (2022)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
por: Egan, Michael F., et al.
Publicado: (2019)

Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data
por: Ho, Chang Y., et al.
Publicado: (2020)

Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
por: Voss, Tiffini, et al.
Publicado: (2023)

Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐AD
por: Oblak, Adrian L., et al.
Publicado: (2020)

Inhibition of serum- and glucocorticoid-induced kinase 1 ameliorates hydrocephalus in preclinical models
por: Hochstetler, Alexandra, et al.
Publicado: (2023)

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPP(swe) Mice Without Inducing Microhemorrhage
por: Villarreal, Stephanie, et al.
Publicado: (2017)

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects
por: Forman, Mark, et al.
Publicado: (2019)

Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging
por: Maharjan, Surendra, et al.
Publicado: (2022)

Corrigendum: Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging
por: Maharjan, Surendra, et al.
Publicado: (2022)

Natural genetic variation determines microglia heterogeneity in wild-derived mouse models of Alzheimer’s disease
por: Yang, Hongtian Stanley, et al.
Publicado: (2021)

Enhancing face validity of mouse models of Alzheimer’s disease with natural genetic variation
por: Onos, Kristen D., et al.
Publicado: (2019)

Genetic context controls early microglia-synaptic interactions in mouse models of Alzheimer’s disease
por: Heuer, Sarah E., et al.
Publicado: (2023)

Determining the Role of ApoE4 in Age-Related Cerebrovascular Decline
por: Foley, Kate, et al.
Publicado: (2020)

Hydrocephalus in a rat model of Meckel Gruber syndrome with a TMEM67 mutation
por: Shim, Joon W., et al.
Publicado: (2019)

Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer’s disease
por: Kesler, Shelli R., et al.
Publicado: (2018)

Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
por: I.R, Macdonald, et al.
Publicado: (2014)

Early life adversity in male mice sculpts reward circuits
por: Wendel, Kara M., et al.
Publicado: (2021)

Altered Brain Adiponectin Receptor Expression in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Pratap, Anishchal A., et al.
Publicado: (2020)

Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis
por: Maiti, Panchanan, et al.
Publicado: (2021)

Correction to: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis
por: Maiti, Panchanan, et al.
Publicado: (2022)

Altered Brain Leptin and Leptin Receptor Expression in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Pratap, Anishchal A., et al.
Publicado: (2020)

Tart Cherry Extract and Omega Fatty Acids Reduce Behavioral Deficits, Gliosis, and Amyloid-Beta Deposition in the 5xFAD Mouse Model of Alzheimer’s Disease
por: Bowers, Zackary, et al.
Publicado: (2021)

ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease
por: Sadleir, Katherine R., et al.
Publicado: (2018)

Retraction Note: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis
por: Maiti, Panchanan, et al.
Publicado: (2023)

Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease
por: Forner, Stefania, et al.
Publicado: (2021)

Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice
por: Sadleir, Katherine R., et al.
Publicado: (2021)

70329 Automated Lungs Segmentation and Airways Skeletonization from CT Scans in Patients with Cystic Fibrosis
por: Chong Chie, Juan A., et al.
Publicado: (2021)

Aromatase Expression in the Hippocampus of AD Patients and 5xFAD Mice
por: Prange-Kiel, Janine, et al.
Publicado: (2016)

Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimer’s Disease Mouse Models
por: Muraoka, Satoshi, et al.
Publicado: (2021)

Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
por: Zarrinmayeh, Hamideh, et al.
Publicado: (2020)

P2X(7) Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches
por: Territo, Paul R., et al.
Publicado: (2021)

Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level
por: Sadleir, Katherine R, et al.
Publicado: (2015)

Axonal and myelinic pathology in 5xFAD Alzheimer’s mouse spinal cord
por: Chu, Tak-Ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_850iclmr8pp6hggo5t9un89h48